Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zotatifin in Mild or Moderate COVID-19
NCT04632381Phase 1Completed
- Sponsor
- eFFECTOR Therapeutics
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zotatifin in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by eFFECTOR Therapeutics. Primary endpoints: Incidence of Treatment Emergent Adverse Events and Serious Adverse Events at 52 days, Incidence of adverse events of special interest at 52 days and 3 more. Started Jul 2021; status: completed.
02
Drugs
zotatifin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04632381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632381.